Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses

Brock, Gerald; McMahon, Chris G.; CHEN, K. K.; Costigan, Timothy M.; Shen, Wei; Watkins, V.; Anglin, Greg; Whitaker, Steve

doi:10.1097/00005392-200210010-00006

Cited by 179 publications

(302 citation statements)

References 11 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…Phosphodiesterase type-5 inhibitors (PDE-5i) were first introduced in 1998 and since then their durability, safety, and efficacy for treating ED have been clearly demonstrated 2–4 .…”

Section: Introductionmentioning

confidence: 99%

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

et al. 2016

View full text Add to dashboard Cite

Purpose Despite the routine use of phosphodiesterase type-5 inhibitors (PDE-5i) for treatment of erectile dysfunction, their role in prostate cancer (PC) chemoprevention remains unclear with only a few studies exploring the link between PDE-5i use and PC. We tested the association between PDE-5i use and PC risk in the REDUCE study. Materials & Methods REDUCE was a four-year multi-center study testing the effect of daily dutasteride on PC risk in men with a PSA of 2.5 to 10.0 ng/mL and a negative biopsy, with men undergoing study-mandated biopsies at 2- and 4-years. The association between PDE-5i use and overall PC risk and disease grade (Gleason 2–6 and 7–10) was examined using adjusted logistic and multinomial regression analysis. Secondary analysis was performed exploring the association between PDE-5i use and PC risk in North American men given the significantly higher use of PDE-5i among these subjects. Results PDE-5i inhibitor use was not associated with PC diagnosis (OR=0.90, 95%CI 0.68–1.20, p=0.476) or low- (OR=0.93, 95%CI 0.67–1.27, p=0.632) or high-grade disease (OR=0.85, 95%CI 0.51–1.39, p=0.508). An inverse trend was seen between PDE-5i use and PC diagnosis in North American men, but was not statistically significant (OR=0.67, 95%CI 0.42–1.07, p=0.091). Conclusions PDE-5i use was not associated with decreased PC diagnosis in post-hoc analysis of the REDUCE study. In North American men, who had a much higher baseline use of PDE-5i, use was associated with an inverse trend of PC diagnosis that approached, but did not reach, statistical significance.

show abstract

“…Phosphodiesterase type-5 inhibitors (PDE-5i) were first introduced in 1998 and since then their durability, safety, and efficacy for treating ED have been clearly demonstrated 2–4 .…”

Section: Introductionmentioning

confidence: 99%

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although oral phosphodiesterase (PDE)-5 inhibitors, drugs that enhance the nitric oxide (NO)-cGMP pathway by inhibiting the hydrolysis of cGMP to inactive GMP, are generally effective and well-tolerated therapies for ED91011, they are not cures for ED and have important limitations. Firstly, PDE5 inhibitors must be used on demand, thus hindering the spontaneity of the sexual act.…”

mentioning

confidence: 99%

Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse

Ryu

Kim

Koh

et al. 2015

Sci Rep

View full text Add to dashboard Cite

Despite the advent of oral phosphodiesterase-5 inhibitors, curative treatment for erectile dysfunction (ED) remains unavailable. Recently, the link between ED and cardiovascular disease was unveiled and the main etiology of ED was found to be vasculogenic. Therefore, neovascularization is a promising strategy for curing ED. Angiopoietin-1 (Ang1) is an angiogenic growth factor that promotes the generation of stable and functional vasculature. Here, we demonstrate that local delivery of the soluble, stable, and potent Ang1 variant, COMP-Ang1 gene or protein, into the penises of hypercholesterolemic mice increases cavernous angiogenesis, eNOS phosphorylation, and cGMP expression, resulting in full recovery of erectile function and cavernous blood flow up to 8 weeks after treatment. COMP-Ang1-induced promotion of cavernous angiogenesis and erectile function was abolished in Nos3-/- mice and in the presence of the NOS inhibitor, L-NAME. COMP-Ang1 also restored the integrity of endothelial cell-cell junction by down-regulating the expression of histone deacetylase 2 in the penis of hypercholesterolemic mice and in primary cultured mouse cavernous endothelial cells. These findings constitute a new paradigm toward curative treatment of both cavernous angiopathy and ED.

show abstract

“…It has a longer half-life of 17.5 h and performs well from the 16th minute to the 36th hour after per os administration (Eardley et al, 2004). Within the 30th minute and the 36th hour after a per os administration of 20 mg of tadalafil, the sexual success rate is recorded as high as 73% to 80% (Brock et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction

Zhang

Bian

2011

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

It is of great importance to investigate an effective and reliable medication against chronic renal failure (CRF)-related erectile dysfunction (ED), which aims to improve patients' life qualities. The concentrations of cyclic guanosine monophosphate (cGMP) in the corpus cavernosal smooth muscle of both CRF and control rabbits were measured. The effects of various concentrations of tadalafil, papaverine, and sodium nitroprusside on the relaxation responses of corpus cavernosal smooth muscle pre-contracted with phenylephrine in CRF rabbits were observed. There was significant difference in the concentration of cGMP between CRF and control rabbits (P<0.01). Tadalafil had the greatest impacts on CRF rabbits when given the same concentration of papaverine or sodium nitroprusside and particularly significant differences were identified under the concentration levels of 10 −5 and 10 −4 mol/L (P<0.01). The results suggest that the cGMP concentrations of the corpus cavernosum had been greatly reduced in CRF rabbits compared with control rabbits and that tadalafil may be an ideal medication for use in the treatment of CRF-related ED.

show abstract

Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses

Abstract: Tadalafil was effective and well tolerated in this patient population.

Cited by 179 publications

References 11 publications

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse

Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction

Contact Info

Product

Resources

About